Analysis Demonstrates RSV Will Easily Mutate to Escape Monoclonal Antibodies
PETER MCCULLOUGH, MD JAN 11, 2024 READ | LISTEN
The US FDA repeatedly pulled monoclonal antibodies against SARS-CoV-2 off the market because modeling studies demonstrated emerging mutational resistance. I wondered if the same challenges will exist for nirsevimab (Beyfortis, Sanofi, AstraZeneca) which have been injected in newborns on a mass indiscriminate basis since October, 2023 for the theoretical prevention of respiratory syncytial virus (RSV).